Abstract: A new pharmaceutical composition for treatment and prevention of cardiovascular disease, and increasing immune function contains Ginsenoside, Ophiopogonin, Sesquicarene and Chamigrene. Processes for producing these components and the composition, referred to as Pure San-Mai-Sen (PSMS), are provided.

Abstract: The invention relates to novel pharmaceutical compositions containing ubiquinone, particularly Coenzyme Q.sub.10, and mixtures of phospholipids having organic or vegetal origin, in weight-ratios ranging from 1/1 to 1/100,000, together with pharmaceutically acceptable excipients.The pharmaceutical compositions of the invention are useful in the treatment of pathological conditions related to insufficient cerebral perfusion, atherosclerosis or enzymatic impairments involving cerebral metabolic deficiencies, and generally in conditions deriving from cerebral and tissular postanoxy.Said pharmaceutical composition allows a better absorption of Coenzyme Q.sub.10.

Abstract: Pharmaceutical compositions containing imidazolidinetrione derivatives or pharmaceutically acceptable salts thereof having hypoglycemic and hypolipidemic effects. The compositions comprise as an active ingredient at least one imidazolidinetrione derivative of the formula: ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, an alkyl group, a cycloalkyl group or ##STR2## and each of R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, halogen, a nitro group, a lower alkyl group or a lower alkoxy group.

Abstract: This invention relates to a compound of formula (I) ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy; and R.sub.3 is a C.sub.7 -C.sub.9 aralkyl, the phenyl nucleus of which can be mono-, di-, or trisubstituted by halogen, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy, and nontoxic, pharmaceutically acceptable salts thereof. The compounds have useful antithrombic properties.

Abstract: Pharmaceutical compositions containing 2,4,6-triiodophenol are useful for treating a variety of medical conditions, for example, atherosclerosis.

Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) or (II): ##STR1## wherein: n is 1 to 5;R is hydrogen or ##STR2## R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; andR.sup.3 is hydrogen, C.sub.1-5 alkyl or C.sub.1-5 alkyl substituted with a member of the group consisting of phenyl, dimethylamino, or acetylamino; andthe dotted lines at a, b and c represent optional double bonds and pharmaceutically acceptable salts of the compounds (II) in which R.sup.3 is hydrogen are disclosed.

Abstract: Certain 6-(substituted-naphthyl)hydrocarbyl-4-hydroxytetrahydropyran-2-ones are unexpectedly potent in the treatment of familial hypercholesterolemia, hyperlipemia and atherosclerosis by virtue of their ability to inhibit the enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase).

Abstract: Compounds of formula (I): ##STR1## [wherein X represents a hydrogen atom or a 2-methylbutyryl group, Y represents a hydrogen atom or a methyl group and R.sup.1 and R.sup.2 are the same or different and each represents an oxygen atom or a group of formula .dbd.N--OR.sup.3 (wherein R.sup.3 represents a hydrogen atom or an alkyl group)], the free hydroxy-carboxylic acids corresponding thereto and salts and esters of said acids may be prepared by oxidizing and, if necessary, oximating a corresponding ML-236A, ML-236B, MB-530A or MB-530B compound, and these compounds have valuable antihypercholesteraemic activity.

Abstract: This disclosure describes novel diaryl-alkanamides. These compounds are useful as pharmaceutical agents for ameliorating atherosclerosis by inhibiting the formation and development of atherosclerotic lesions in the arterial wall of mammals.

Abstract: A medical agent for suppressing arteriosclerosis or a hypolipemic agent comprising a composition containing nicardipine or a pharmaceutically acceptable salt thereof as the effective component.

Abstract: New substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides which are useful as anti-arteriosclerotic agents are disclosed. These compounds elevate the high density lipoprotein fraction of cholesterol, and also lower the low density lipoprotein fraction of cholesterol.

Abstract: The invention relates to water-soluble alkali salts of mono- and disulfonic acid derivatives and mono- and disulfonamide derivatives of 6,6'-methylene-bis-(2,2,4-trimethyl-1,2-dihydroquinoline) and dimer and/or trimer condensation products thereof bound with a methylene bridge at the 8 or 8' position. The new compounds are radioprotective and radiosensibilizers at the same time, and may be used both in the therapy and prophylaxis of malignant tumors.